Kaplan-Meier survival analysis also demonstrated that among patients with KIRC (P = 0.002), STAD (P = 0.003), and THYM (P = 0.019), those with high levels of MSH2 had longer survival times, while in patients with ACC (P = 0.025), LGG (P = 0.006), LIHC (P < 0.001), MESO (P = 0.037), PAAD (P < 0.002), SARC (P = 0.007), and UCEC (P = 0.005), high MSH2 expression was associated with poor OS (Figure 3). This evidence concerns the gene MSH2 and adrenal cortex carcinoma.